Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.37 |
| ▸ | CTSS | P25774 | 7/20 | 0.36 |
| ▸ | CTSK | P43235 | 6/20 | 0.36 |
| ▸ | ELANE | P08246 | 2/20 | 0.35 |
| ▸ | CTSV | O60911 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | CMA1 | P23946 | 1/20 | 0.35 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12401550 | 0.94 | CTSK (0.37) | CPB2CTSSCTSKELANECTSV | |
| SCHEMBL12401741 | 0.94 | CTSK (0.37) | CPB2CTSSCTSKELANECTSV | |
| SCHEMBL12401557 | 0.86 | CPB2 (0.37) | CPB2CTSSCTSKELANECTSV | |
| SCHEMBL12401556 | 0.86 | CPB2 (0.37) | CPB2CTSSCTSKELANECTSV | |
| SCHEMBL12401659 | 0.82 | CPB2 (0.38) | CPB2CTSSCTSKELANECTSV | |
| SCHEMBL12401640 | 0.81 | CPB2 (0.38) | CPB2CTSSCTSKELANECTSV | |
| SCHEMBL12401749 | 0.80 | CTSK (0.47) | CPB2CTSSCTSKELANECTSV | |
| SCHEMBL12401547 | 0.80 | CTSS (0.37) | CPB2CTSSCTSKELANECTSV | |
| SCHEMBL12401544 | 0.80 | CTSS (0.37) | CPB2CTSSCTSKELANECTSV | |
| SCHEMBL13117649 | 0.79 | CTSK (0.40) | CPB2CTSSCTSKELANECTSV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440706-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-14 | — | — | US | disclosed |
| US-8372873-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-12 | — | — | US | disclosed |
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-28 | — | — | US | disclosed |
| US-20110165120-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-07 | — | — | US | disclosed |
| US-7964624-B1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110165120-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, PRSS3, PRSS2 | CPB2 109/4885CTSS 67/4885CTSK 217/4885 |
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, SPINT2, PRSS2 | CPB2 92/4885CTSS 77/4885CTSK 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.